Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.


Journal Article

BACKGROUND: Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm. METHODS AND RESULTS: This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of

Full Text

Duke Authors

Cited Authors

  • Massie, BM; Collins, JF; Ammon, SE; Armstrong, PW; Cleland, JGF; Ezekowitz, M; Jafri, SM; Krol, WF; O'Connor, CM; Schulman, KA; Teo, K; Warren, SR; WATCH Trial Investigators,

Published Date

  • March 31, 2009

Published In

Volume / Issue

  • 119 / 12

Start / End Page

  • 1616 - 1624

PubMed ID

  • 19289640

Pubmed Central ID

  • 19289640

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.108.801753


  • eng

Conference Location

  • United States